Acomplia is an anorectic anti-obesity drug. Since Acomplia is a CB1 cannabinoid receptor antagonist, Acomplia’s main effect is appetite reduction.

Acomplia helps people to lose weight. This product is also supposed to help patients in other ways. There is also proof that it helps with lipid levels, for example cholesterol, in the blood and can help with other metabolism-related health problems.

Acomplia is also considered to help smokers to give up smoking.

Acomplia also has been shown to help control blood pressure (reducing it) as it lowers the levels of fat and sugar found in the body.

According to some researches Acomplia is supposed to help to improve your short-term memory. A chemical called tetrahydrocannabinol is known to adversely affect your memory storage. There is evidence that Acomplia blocks the effect of this member of the cannabinoid family and allows the rats to improve their memory recall. Trials are underway to find out whether the same effect is replicated in humans.

Acomplia weight loss pills are approved now and available in all of 25 European Union Countries.

The European Commission have approved the sale of Acomplia weight loss drugs for treating obesity, weight loss and quitting smoking as well.

The approval of Acomplia in the European Union is important news for obese and overweight patients with additional cardiometabolic risk factors such as type 2 diabetes or dyslipidaemia who will now have access to an innovative treatment option.